CRCA is a single-stock leveraged ETF managed by ProShares, the largest provider of leveraged and inverse ETFs. The fund seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of Circle Internet Group, Inc. (NYSE: CRCL), the financial technology company behind the USDC stablecoin.
Rather than holding a diversified basket, the fund concentrates its exposure on a single underlying security, using total return swaps with multiple counterparties to achieve its leveraged objective. In practice, its portfolio is effectively 100% tied to the price of CRCL, with the remainder held as cash and collateral. The fund is non-diversified and carries a net expense ratio of 0.95%.
This concentrated, leveraged structure explains why CRCA's ETF performance is so volatile. Because the underlying stock has been in a steep downtrend, the daily 2x reset has magnified those losses, while the compounding effect of daily rebalancing has added further drag during sustained, choppy declines. When assessing similar products, I sometimes cross-check sector momentum with Tickeron’s AI Screener to see how CRCA stacks up against peers.
CRCA's recent price movement has been sharply negative and trend-driven rather than range-bound. Approximately 30 days ago, the fund traded near $16.90 per share. As of the latest available session, it was near $7.84, representing a decline of roughly 54% over the period.
The quarterly picture is similarly weak. From roughly $16.50 in mid-August, CRCA has fallen approximately 52%. This trajectory reflects both the decline in the underlying CRCL stock and the mathematical effect of daily leverage. In a falling market, a leveraged fund can lose more than twice the underlying's percentage decline over multi-day periods, because each day's reset compounds from a lower base.
The dominant driver of CRCA's ETF price movement has been a sell-off in Circle Internet Group shares. Circle generates roughly three-quarters of its revenue from interest earned on the cash and short-term U.S. Treasuries that back USDC. As the Federal Reserve has cut interest rates, the yield on those reserves has fallen, directly compressing Circle's core earnings.
In its most recent quarterly results, Circle reported that reserve income declined 8% year over year, with the return rate on reserves falling 61 basis points to 3.5%. Although total revenue rose, the increase was driven largely by a one-time token presale, while the underlying reserve business decelerated. Circle also disclosed a reduction of about 5% of its workforce, underscoring cost pressures tied to the lower-rate environment.
Competitive dynamics have added further pressure. New yield-sharing stablecoin initiatives backed by large payment and financial firms have raised questions about USDC's long-term market position. USDC circulation ended the latest quarter at roughly $73.9 billion, flat year over year, while its share of the dollar stablecoin market slipped to about 27%.
The three-month trend reflects a broader repricing of Circle's business model. Beyond the near-term earnings catalysts, investors have reassessed the sustainability of reserve-based income as interest rates normalize, alongside rising competition from bank-issued and yield-sharing stablecoins.
Regulatory developments have also shaped sentiment. U.S. stablecoin legislation and related rulemaking have introduced uncertainty around reserve income and distribution economics. Combined with the post-IPO lockup expiration that created incremental selling pressure in the underlying stock, these factors have sustained a downward bias in CRCL that CRCA's leverage has mechanically amplified. The absence of meaningful diversification means the fund has had no offsetting sector or factor exposure to cushion the decline.
Going forward, the factors most likely to influence CRCA are those affecting Circle's fundamentals and the broader interest-rate environment. The path of Federal Reserve policy remains central: additional rate cuts would further compress Circle's reserve income, while a pause or a firmer yield backdrop could ease that pressure.
Investors should also monitor USDC circulation trends and stablecoin market share, competitive product launches from payment networks and banks, and the implementation of U.S. stablecoin regulation. Circle's efforts to diversify revenue through payments infrastructure and its Arc blockchain will be important to whether earnings become less sensitive to rates. Finally, because CRCA is a leveraged, daily-reset product, its performance can diverge meaningfully from the underlying stock over time, making volatility decay and holding-period mechanics key considerations for anyone evaluating the fund.
I’ve found Tickeron’s AI Screener helpful when evaluating leveraged single-stock ETFs like CRCA. The platform lets me scan thousands of securities with technical indicators, fundamentals, volatility metrics, price patterns, and AI-generated signals. It surfaces potential comparables and momentum trends efficiently, which adds useful context when reviewing concentrated products in a volatile sector. This kind of structured screening supports a more systematic approach to idea generation without replacing individual analysis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
CRCA saw its Momentum Indicator move below the 0 level on October 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator turned negative. In 22 of the 24 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CRCA turned negative on October 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 8 similar instances when the indicator turned negative. In 8 of the 8 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRCA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CRCA entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +11.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRCA advanced for three days, in 50 of 57 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
CRCA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.